"Quinazolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011799
|
| MeSH Number(s) |
D03.633.100.786
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinazolines".
Below are MeSH descriptors whose meaning is more specific than "Quinazolines".
This graph shows the total number of publications written about "Quinazolines" by people in this website by year, and whether "Quinazolines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 5 | 1 | 6 |
| 2004 | 2 | 1 | 3 |
| 2005 | 4 | 2 | 6 |
| 2006 | 3 | 5 | 8 |
| 2007 | 7 | 4 | 11 |
| 2008 | 5 | 5 | 10 |
| 2009 | 5 | 2 | 7 |
| 2010 | 9 | 3 | 12 |
| 2011 | 3 | 5 | 8 |
| 2012 | 9 | 0 | 9 |
| 2013 | 6 | 7 | 13 |
| 2014 | 5 | 5 | 10 |
| 2015 | 5 | 3 | 8 |
| 2016 | 4 | 1 | 5 |
| 2017 | 2 | 3 | 5 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2021 | 3 | 0 | 3 |
| 2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinazolines" by people in Profiles.
-
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 2024 Apr 15; 130(8):1234-1245.
-
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3101-3109.
-
Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. J Clin Oncol. 2022 03 01; 40(7):710-718.
-
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMBÂ trial). Eur J Cancer. 2021 08; 153:223-233.
-
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. Eur J Cancer. 2021 05; 149:235-248.
-
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. Mol Cancer Ther. 2020 04; 19(4):1031-1039.
-
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. Oral Oncol. 2019 10; 97:82-91.
-
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019 04 01; 30(4):551-557.
-
RET rearrangements are actionable alterations in breast cancer. Nat Commun. 2018 11 16; 9(1):4821.
-
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017 12 21; 377(25):2433-2444.